Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Treasury Shares (2022 - 2025)

Historic Treasury Shares for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $6.3 million.

  • Taysha Gene Therapies' Treasury Shares rose 3785.37% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 3785.37%. This contributed to the annual value of $4.5 million for FY2024, which is 111296.54% up from last year.
  • Per Taysha Gene Therapies' latest filing, its Treasury Shares stood at $6.3 million for Q3 2025, which was up 3785.37% from $6.3 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Treasury Shares ranged from a high of $6.3 million in Q2 2025 and a low of $375044.0 during Q3 2023
  • Over the past 4 years, Taysha Gene Therapies' median Treasury Shares value was $1.9 million (recorded in 2022), while the average stood at $3.0 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Treasury Shares crashed by 7018.36% in 2023, and later soared by 111296.54% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' Treasury Shares (Quarter) stood at $1.3 million in 2022, then tumbled by 70.18% to $375044.0 in 2023, then skyrocketed by 1112.97% to $4.5 million in 2024, then skyrocketed by 37.85% to $6.3 million in 2025.
  • Its Treasury Shares stands at $6.3 million for Q3 2025, versus $6.3 million for Q2 2025 and $6.2 million for Q1 2025.